OBJECTIVE: To measure plasma levels of osteopontin in patients with transitional cell carcinoma (TCC) of the bladder, and to determine if osteopontin levels relate to disease stage. PATIENTS AND METHODS: Blood samples were collected from 72 consecutive patients with TCC. Clinical data were obtained from medical record reviews. Patients were divided into subgroups based on disease status (active vs inactive) and clinical and pathological stage of TCC (tumour, nodes and metastases staging system). Osteopontin levels were measured using an enzyme-linked immunosorbent assay. RESULTS: Plasma osteopontin levels were higher in patients with active TCC than in controls (P = 0.035). Plasma osteopontin levels were not significantly different between patients with active and inactive TCC, but were higher in patients with metastases than in patients with active, clinically organ-confined TCC (P = 0.021). CONCLUSIONS: Plasma osteopontin levels increase with tumour stage in TCC of the bladder. These findings suggest that larger, more extended studies on plasma osteopontin levels in patients with TCC are warranted.
OBJECTIVE: To measure plasma levels of osteopontin in patients with transitional cell carcinoma (TCC) of the bladder, and to determine if osteopontin levels relate to disease stage. PATIENTS AND METHODS: Blood samples were collected from 72 consecutive patients with TCC. Clinical data were obtained from medical record reviews. Patients were divided into subgroups based on disease status (active vs inactive) and clinical and pathological stage of TCC (tumour, nodes and metastases staging system). Osteopontin levels were measured using an enzyme-linked immunosorbent assay. RESULTS: Plasma osteopontin levels were higher in patients with active TCC than in controls (P = 0.035). Plasma osteopontin levels were not significantly different between patients with active and inactive TCC, but were higher in patients with metastases than in patients with active, clinically organ-confined TCC (P = 0.021). CONCLUSIONS: Plasma osteopontin levels increase with tumour stage in TCC of the bladder. These findings suggest that larger, more extended studies on plasma osteopontin levels in patients with TCC are warranted.
Authors: Mansoor Ahmed; Joseph L Sottnik; Garrett M Dancik; Divya Sahu; Donna E Hansel; Dan Theodorescu; Martin A Schwartz Journal: Cancer Cell Date: 2016-09-01 Impact factor: 31.743
Authors: Azizbek Ramankulov; Michael Lein; Glen Kristiansen; Hellmuth-A Meyer; Stefan A Loening; Klaus Jung Journal: J Cancer Res Clin Oncol Date: 2007-05-04 Impact factor: 4.553
Authors: Akeila Bellahcène; Vincent Castronovo; Kalu U E Ogbureke; Larry W Fisher; Neal S Fedarko Journal: Nat Rev Cancer Date: 2008-03 Impact factor: 60.716
Authors: A Alcaraz; R González-López; J Morote; C de la Piedra; C Meseguer; E Esteban; M Climent; B González-Gragera; J-L Alvarez-Ossorio; I Chirivella; B Mellado; P-C Lara; F Vázquez; J-A Contreras; J Carles; A Murias; V Calderero; J Comet-Batlle; A González-Del Alba; L León-Mateos; A Mañas; J Segarra; A Lassa; C González-Enguita; M-J Méndez; P Samper; M Unda; I Mahillo-Fernández; J Bellmunt Journal: Br J Cancer Date: 2013-06-25 Impact factor: 7.640
Authors: Janet P C Wong; Ran Wei; Peng Lyu; Olivia L H Tong; Shu Dong Zhang; Qing Wen; Hiu Fung Yuen; Mohamed El-Tanani; Hang Fai Kwok Journal: Int J Biol Sci Date: 2017-11-01 Impact factor: 6.580
Authors: Syed A Hussain; Daniel H Palmer; Wing-Kin Syn; Joseph J Sacco; Richard M D Greensmith; Taha Elmetwali; Vijay Aachi; Bryony H Lloyd; Puthen V Jithesh; John Arrand; Darren Barton; Jawaher Ansari; D Ross Sibson; Nicholas D James Journal: Int J Oncol Date: 2017-03-02 Impact factor: 5.650